SCHEMBL713544

SCHEMBL713544

Cc1ccccc1-c1cnc2[nH]c(-c3cc(OCc4ccccc4)ccc3OC(C)C)nc2c1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 0.40
PRMT5 O14744 3/20 0.39
FGFR2 P21802 1/20 0.37
FGFR3 P22607 1/20 0.37
PPARD Q03181 1/20 0.36
MCL1 Q07820 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
KIT P10721 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
TLR8 Q9NR97 1/20 0.35
PDE5A O76074 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713547 0.93 PRMT5 (0.39) FFAR1PRMT5FGFR2FGFR3MCL1
SCHEMBL10206516 0.92 MCL1 (0.41) PPARDMCL1PDGFRBPDGFRAMAOA
SCHEMBL712000 0.90 PRMT5 (0.38) FFAR1PRMT5PPARDMCL1PDGFRB
SCHEMBL712803 0.90 MAPT (0.44) FFAR1PRMT5PDGFRBPDGFRA
SCHEMBL710136 0.88 MAPT (0.43) PRMT5MCL1PDGFRBPDGFRAKIT
SCHEMBL711145 0.88 SCD (0.42) FFAR1MCL1PDGFRBPDGFRAFFAR4
SCHEMBL13639547 0.88 PDGFRB (0.39) MCL1PDGFRBPDGFRAPDE5AMAOA
SCHEMBL711592 0.88 MCL1 (0.40) PRMT5MCL1PDGFRBPDGFRA
SCHEMBL719831 0.88 MAP4K4 (0.43) PRMT5MCL1
SCHEMBL709840 0.87 GRIN1 (0.42) PRMT5PDGFRBPDGFRAKITTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK FFAR1 3394/4885PRMT5 2373/4885FGFR2 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.